First Edition of Saudi Film Confex Set to Debut in Riyadh
RIYADH, Aug 8, 2023 – (ACN Newswire) – The Saudi Film Commission is expected to…
News
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical…
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR)…
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS-…
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP)…
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
First patients dosed in the BDC-1001 Phase 2 program BDC-1001 Phase 1 data presented at…
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of…
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with…
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader…
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic…
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of…
T2 Biosystems Announces Second Quarter 2023 Financial Results
Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel…
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment…
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European…
Tilray Brands Announces Agreement to Acquire Eight Beer & Beverage Brands From Anheuser-Busch, Fueling Tilray’s Future in the U.S. Craft Beer Industry
Acquisition is Expected to Position Tilray as the 5th1 Largest Craft Beer Brewer in the…
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDA Submitted an…
Shockwave Medical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
FibroGen Reports Second Quarter 2023 Financial Results
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer…
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24%…
Cara Therapeutics Reports Second Quarter 2023 Financial Results
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share…